Literature DB >> 15259122

Artificially low hemoglobin A1c caused by use of dapsone.

Eric S Albright1, Fernando Ovalle, Davis S H Bell.   

Abstract

OBJECTIVE: To describe a case of artifactually decreased hemoglobin Alc (HbAlc) attributable to use of dapsone.
METHODS: We present a detailed case report and results of a related literature search. In addition, potential causes of artifactually lowered HbAlc values are discussed.
RESULTS: A 35-year-old patient with type I diabetes had high home-monitored blood glucose values, high clinic plasma glucose determinations, increased fructosamine levels, and low HbAlc values. The lowering of the HbAlc level was associated with use of dapsone, and the decrease in HbAlc value was proportional to the dose of dapsone. A literature search revealed one previous report of artifactual lowering of the HbAlc value, in which high methemoglobin levels were found and thought to be the cause of the artifactually decreased HbA1c.
CONCLUSION: By increasing methemoglobin levels and decreasing erythrocyte survival, dapsone can artifactually lower HbA1c. Clinicians should be aware of this potential side effect of dapsone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15259122     DOI: 10.4158/EP.8.5.370

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  9 in total

Review 1.  The Effects of Vitamin D Supplementation in Newly Diagnosed Type 1 Diabetes Patients: Systematic Review of Randomized Controlled Trials.

Authors:  Elina Gregoriou; Ioannis Mamais; Irene Tzanetakou; Giagkos Lavranos; Stavri Chrysostomou
Journal:  Rev Diabet Stud       Date:  2017-10-10

2.  Tacrolimus trough monitoring guided by mass spectrometry without accounting for assay differences is associated with acute kidney injury in lung transplant recipients.

Authors:  Nicholas A Kolaitis; Daniel R Calabrese; Patrick Ahearn; Aida Venado; Rebecca Florez; Huey-Ling Lei; Karolina Isaak; Erik Henricksen; Emily Martinez; Tiffany Chong; Rupal J Shah; Lorriana E Leard; Mary Ellen Kleinhenz; Jeffrey Golden; Teresa De Marco; John R Greenland; Jasleen Kukreja; Steven R Hays; Paul D Blanc; Jonathan P Singer
Journal:  Am J Health Syst Pharm       Date:  2019-12-02       Impact factor: 2.637

Review 3.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

4.  Falsely Decreased HbA1c in a Type 2 Diabetic Patient Treated with Dapsone.

Authors:  Arti D Shah; Rena K Fox; Robert J Rushakoff
Journal:  Endocr Pract       Date:  2014-11       Impact factor: 3.443

5.  Spurious HbA1c results in patients with diabetes treated with dapsone.

Authors:  Khaled Aljenaee; Osamah Hakami; Colin Davenport; Gemma Farrell; Tommy Kyaw Tun; Agnieszka Pazderska; Niamh Phelan; Marie-Louise Healy; Seamus Sreenan; John H McDermott
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-09-27

6.  Unexpectedly low HbA1c levels in two diabetes patients following dapsone use.

Authors:  Ranjit Unnikrishnan; Ranjit Mohan Anjana; Ramamurthy Jayashri; Viswanathan Mohan
Journal:  Indian J Endocrinol Metab       Date:  2012-07

7.  Drugs affecting HbA1c levels.

Authors:  Ranjit Unnikrishnan; Ranjit Mohan Anjana; Viswanathan Mohan
Journal:  Indian J Endocrinol Metab       Date:  2012-07

8.  Drug-Induced Falsely Low A1C: Report of a Case Series From a Diabetes Clinic.

Authors:  Kirsten Mitchell; Babu Mukhopadhyay
Journal:  Clin Diabetes       Date:  2018-01

Review 9.  The Oral Glucose Tolerance Test: 100 Years Later.

Authors:  Ram Jagannathan; João Sérgio Neves; Brenda Dorcely; Stephanie T Chung; Kosuke Tamura; Mary Rhee; Michael Bergman
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-19       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.